Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).
作者： Fei Ma , Peng Liu , Min Lei , Jian Liu , Hongtao Wang
DOI: 10.1016/J.EJMECH.2016.12.038
关键词:
摘要: Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately one third of acute myeloid leukemia (AML) patients, which has been proposed as a promising …
sci-hub.se 参考文章(33)
Mark Levis, Farhad Ravandi, Eunice S. Wang, Maria R. Baer, Alexander Perl, Steven Coutre, Harry Erba, Robert K. Stuart, Michele Baccarani, Larry D. Cripe, Martin S. Tallman, Giovanna Meloni, Lucy A. Godley, Amelia A. Langston, Sergio Amadori, Ian D. Lewis, Arnon Nagler, Richard Stone, Karen Yee, Anjali Advani, Dan Douer, W. Wiktor-Jedrzejczak, Gunnar Juliusson, Mark R. Litzow, Stephen Petersdorf, Miguel Sanz, Hagop M. Kantarjian, Takashi Sato, Lothar Tremmel, Debra M. Bensen-Kennedy, Donald Small, B. Douglas Smith, Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse Blood. ,vol. 117, pp. 3294- 3301 ,(2011) , 10.1182/BLOOD-2010-08-301796
Cheuk Him Man, Tsz Kan Fung, Christa Ho, Heron H. C. Han, Howard C. H. Chow, Alvin C. H. Ma, William W. L. Choi, Si Lok, Alice M. S. Cheung, Connie Eaves, Yok Lam Kwong, Anskar Y. H. Leung, Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. Blood. ,vol. 119, pp. 5133- 5143 ,(2012) , 10.1182/BLOOD-2011-06-363960
K W Pratz, E Cho, M J Levis, J E Karp, S D Gore, M McDevitt, A Stine, M Zhao, S D Baker, M A Carducci, J J Wright, M A Rudek, B D Smith, A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias Leukemia. ,vol. 24, pp. 1437- 1444 ,(2010) , 10.1038/LEU.2010.132
Shuli Zhang, Hal E. Broxmeyer, p85 subunit of PI3 kinase does not bind to human Flt3 receptor, but associates with SHP2, SHIP, and a tyrosine-phosphorylated 100-kDa protein in Flt3 ligand-stimulated hematopoietic cells. Biochemical and Biophysical Research Communications. ,vol. 254, pp. 440- 445 ,(1999) , 10.1006/BBRC.1998.9959
Viktor Grünwald, Hans Heinzer, Walter Fiedler, Managing side effects of angiogenesis inhibitors in renal cell carcinoma. Onkologie. ,vol. 30, pp. 519- 524 ,(2007) , 10.1159/000107721
Stephan Metzelder, Ying Wang, Ellen Wollmer, Michael Wanzel, Sabine Teichler, Anuhar Chaturvedi, Martin Eilers, Erich Enghofer, Andreas Neubauer, Andreas Burchert, Compassionate use of sorafenib in FLT3-ITD―positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation Blood. ,vol. 113, pp. 6567- 6571 ,(2009) , 10.1182/BLOOD-2009-03-208298
L. C. Cantley, The Phosphoinositide 3-Kinase Pathway Science. ,vol. 296, pp. 1655- 1657 ,(2002) , 10.1126/SCIENCE.296.5573.1655
Hitoshi Kiyoi, Ryuzo Ohno, Ryuzo Ueda, Hidehiko Saito, Tomoki Naoe, Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain Oncogene. ,vol. 21, pp. 2555- 2563 ,(2002) , 10.1038/SJ.ONC.1205332
Maria Jönsson, Maria Engström, Jan-Ingvar Jönsson, FLT3 ligand regulates apoptosis through AKT-dependent inactivation of transcription factor FoxO3. Biochemical and Biophysical Research Communications. ,vol. 318, pp. 899- 903 ,(2004) , 10.1016/J.BBRC.2004.04.110
Catherine C. Smith, Elisabeth A. Lasater, Xiaotian Zhu, Kimberly C. Lin, Whitney K. Stewart, Lauren E. Damon, Sara Salerno, Neil P. Shah, Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Blood. ,vol. 121, pp. 3165- 3171 ,(2013) , 10.1182/BLOOD-2012-07-442871